|  |
June 2004 Stock Report
| Company |
6/30/04 Close |
% of 52wk High |
% change from 6/27/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| HUMAN GENOME SCIENCES |
$11.63 |
70% |
-7% |
$1,509 |
$901 |
$504 |
$1,112 |
$1.0 |
-$222 |
4.1 |
Dec-93 |
3.9 |
$3.00 |
$176 |
| INCYTE CORP. |
$7.64 |
75% |
62% |
$556 |
$510 |
$418 |
$463 |
$1.0 |
-$151 |
3.4 |
Nov-93 |
4.1 |
$1.88 |
$47 |
| MILLENNIUM PHARMACEUTICALS |
$13.80 |
69% |
-12% |
$4,206 |
$867 |
$204 |
$3,542 |
$2.3 |
-$162 |
5.3 |
May-96 |
4.6 |
$3.00 |
$273 |
| MYRIAD GENETICS |
$14.92 |
77% |
5% |
$405 |
$130 |
$0 |
$275 |
$0.5 |
-$43 |
3.0 |
Oct-95 |
1.7 |
$9.00 |
$163 |
| OSCIENT PHARMACEUTICALS |
$5.11 |
71% |
90% |
$380 |
$84 |
$24 |
$320 |
$5.1 |
-$78 |
1.1 |
Feb-82 |
0.5 |
$11.00 |
$90 |
| 1st Generation Genomics Average |
|
72% |
27% |
$1,411 |
$498 |
|
$1,143 |
$2.0 |
-$131 |
3.4 |
|
2.9 |
|
|
| 1st Generation Genomics Median |
|
73% |
33% |
$481 |
$320 |
|
$392 |
$1.0 |
-$114 |
3.2 |
|
2.8 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/30/04 Close |
% of 52wk High |
% change from 6/27/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ACLARA BIOSCIENCES |
$4.48 |
96% |
10% |
$162 |
$86 |
$0 |
$76 |
$1.2 |
-$107 |
0.8 |
Mar-00 |
0.2 |
$21.00 |
$682 |
| AFFYMETRIX |
$32.73 |
86% |
69% |
$1,978 |
$216 |
$120 |
$1,882 |
$2.2 |
-$7 |
30.0 |
Jun-96 |
4.4 |
$7.50 |
$287 |
| CALIPER LIFE SCIENCES |
$4.65 |
47% |
10% |
$135 |
$60 |
$2 |
$77 |
$0.2 |
-$40 |
1.5 |
Dec-99 |
0.3 |
$16.00 |
$333 |
| CEPHEID |
$11.54 |
85% |
159% |
$481 |
$74 |
$10 |
$417 |
$2.3 |
-$16 |
4.5 |
Jun-00 |
1.9 |
$6.00 |
$158 |
| CIPHERGEN BIOSYSTEMS |
$7.32 |
52% |
-26% |
$213 |
$43 |
$32 |
$202 |
$0.6 |
-$30 |
1.4 |
Sep-00 |
0.5 |
$16.00 |
$417 |
| COMBIMATRIX CORP. |
$4.35 |
47% |
77% |
$134 |
$19 |
$0 |
$115 |
$2.0 |
na |
na |
na |
na |
na |
na |
| COMPUGEN LTD |
$4.74 |
59% |
-3% |
$129 |
$20 |
$0 |
$109 |
$0.6 |
-$12 |
1.7 |
Sep-00 |
0.5 |
$10.00 |
$0 |
| ILLUMINA |
$6.33 |
62% |
121% |
$210 |
$28 |
$25 |
$207 |
$5.7 |
-$16 |
1.8 |
Jul-00 |
0.4 |
$16.00 |
$515 |
| NANOGEN |
$6.77 |
45% |
171% |
$230 |
$64 |
$1 |
$168 |
$1.2 |
-$22 |
2.9 |
Apr-98 |
0.6 |
$11.00 |
$197 |
| ORCHID BIOSCIENCES |
$7.70 |
54% |
38% |
$169 |
$34 |
$2 |
$137 |
$0.3 |
-$28 |
1.2 |
May-00 |
1.0 |
$8.00 |
$263 |
| SEQUENOM |
$1.46 |
32% |
-47% |
$58 |
$55 |
$15 |
$18 |
$0.1 |
-$40 |
1.4 |
Feb-00 |
0.1 |
$26.00 |
$609 |
| TRANSGENOMIC |
$1.32 |
40% |
-35% |
$38 |
$5 |
$6 |
$40 |
$0.2 |
-$16 |
0.3 |
Jul-00 |
0.1 |
$15.00 |
$317 |
| Genomic Supply Average |
|
59% |
45% |
$328 |
$59 |
|
$287 |
$1.4 |
-$30 |
4.3 |
|
0.9 |
|
|
| Genomic Supply Median |
|
54% |
38% |
$162 |
$43 |
|
$115 |
$1.0 |
-$19 |
1.5 |
|
0.5 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/30/04 Close |
% of 52wk High |
% change from 6/27/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ARENA PHARMACEUTICALS |
$5.46 |
64% |
-19% |
$140 |
$149 |
$0 |
-$10 |
-$0.0 |
-$47 |
3.2 |
Jul-00 |
0.3 |
$18.00 |
$394 |
| CELERA GENOMICS GROUP |
$11.51 |
64% |
10% |
$840 |
$749 |
$6 |
$97 |
$0.1 |
-$88 |
8.6 |
Feb-00 |
0.1 |
$225.00 |
na |
| CURAGEN CORP. |
$6.01 |
63% |
14% |
$301 |
$410 |
$240 |
$131 |
$0.4 |
-$72 |
5.7 |
Mar-98 |
1.0 |
$5.75 |
$143 |
| DECODE GENETICS |
$8.50 |
62% |
166% |
$463 |
$97 |
$62 |
$428 |
$1.0 |
-$48 |
2.0 |
Jul-00 |
0.5 |
$18.00 |
$818 |
| EXELIXIS |
$10.09 |
95% |
42% |
$725 |
$206 |
$108 |
$627 |
$1.1 |
-$115 |
1.8 |
Apr-00 |
0.8 |
$13.00 |
$520 |
| GENAISSANCE PHARMACEUTICALS |
$4.19 |
94% |
167% |
$127 |
$12 |
$11 |
$125 |
$1.2 |
-$19 |
0.7 |
Aug-00 |
0.3 |
$13.00 |
$288 |
| GENE LOGIC |
$4.05 |
63% |
-31% |
$127 |
$114 |
$1 |
$14 |
$0.0 |
-$22 |
5.2 |
Nov-97 |
0.5 |
$8.00 |
$109 |
| GENENCOR INTERNATIONAL |
$16.37 |
94% |
0% |
$971 |
$177 |
$65 |
$859 |
$0.7 |
na |
na |
Jul-00 |
0.9 |
$18.00 |
$1,045 |
| LARGE SCALE BIOLOGY CORP. |
$1.38 |
48% |
33% |
$43 |
$12 |
$0 |
$31 |
$0.4 |
-$17 |
0.7 |
Aug-00 |
0.1 |
$17.00 |
$388 |
| LEXICON GENETICS ORPORATED |
$7.84 |
95% |
20% |
$497 |
$149 |
$56 |
$404 |
$0.6 |
-$62 |
2.4 |
Apr-00 |
0.4 |
$22.00 |
$1,037 |
| LYNX THERAPEUTICS |
$2.30 |
27% |
-38% |
$17 |
$6 |
$0 |
$11 |
$0.1 |
-$17 |
0.4 |
na |
na |
na |
na |
| MAXYGEN |
$10.57 |
68% |
-3% |
$370 |
$129 |
$0 |
$242 |
$0.9 |
-$39 |
3.3 |
Dec-99 |
0.7 |
$16.00 |
$465 |
| NUVELO |
$9.62 |
58% |
75% |
$306 |
$103 |
$19 |
$223 |
$3.5 |
-$71 |
1.5 |
Sep-97 |
0.7 |
$14.00 |
$175 |
| PARADIGM GENETICS |
$0.79 |
46% |
-40% |
$29 |
$16 |
$7 |
$20 |
$0.1 |
-$15 |
1.1 |
May-00 |
0.1 |
$7.00 |
$177 |
| RIGEL PHARMACEUTICALS |
$14.21 |
54% |
37% |
$259 |
$96 |
$3 |
$165 |
$1.3 |
-$52 |
1.8 |
Nov-00 |
2.0 |
$7.00 |
$230 |
| SANGAMO BIOSCIENCES |
$5.97 |
71% |
116% |
$150 |
$42 |
$0 |
$108 |
$1.9 |
-$12 |
3.6 |
Apr-00 |
0.4 |
$15.00 |
$312 |
| ZYMOGENETICS |
$19.00 |
99% |
61% |
$1,005 |
$290 |
$51 |
$766 |
$2.1 |
-$76 |
3.8 |
Feb-01 |
1.6 |
$12.00 |
$547 |
| Genomic Targets Average |
|
68% |
36% |
$375 |
$162 |
|
$249 |
$0.9 |
-$48 |
2.9 |
|
0.6 |
|
|
| Genomic Targets Median |
|
64% |
26% |
$280 |
$109 |
|
$128 |
$0.8 |
-$47 |
2.0 |
|
0.5 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/30/04 Close |
% of 52wk High |
% change from 6/27/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ALEXION PHARMACEUTICALS |
$18.60 |
71% |
7% |
$410 |
$227 |
$120 |
$302 |
$1.6 |
-$61 |
3.7 |
Feb-96 |
2.3 |
$8.25 |
$62 |
| ATHEROGENICS |
$19.03 |
71% |
28% |
$704 |
$117 |
$100 |
$687 |
$7.1 |
-$66 |
1.8 |
Aug-00 |
2.4 |
$8.00 |
$184 |
| CONNETICS CORP. |
$20.20 |
79% |
34% |
$712 |
$50 |
$90 |
$752 |
$3.5 |
na |
na |
Feb-96 |
1.8 |
$11.00 |
$81 |
| CORTECH |
$3.15 |
91% |
12% |
$11 |
$12 |
$0 |
-$0 |
-$0.3 |
-$0 |
29.0 |
Nov-92 |
0.1 |
$40.00 |
$116 |
| CYPRESS BIOSCIENCE |
$13.73 |
82% |
226% |
$403 |
$126 |
$0 |
$277 |
$18.5 |
-$29 |
4.3 |
Dec-83 |
0.2 |
$80.00 |
$33 |
| ICOS CORP. |
$29.84 |
62% |
-21% |
$1,890 |
$377 |
$279 |
$1,791 |
$2.7 |
-$345 |
1.1 |
Jun-91 |
3.7 |
$8.00 |
$172 |
| INKINE PHARMACEUTICAL COMPANY |
$3.87 |
58% |
16% |
$188 |
$11 |
$1 |
$179 |
$3.1 |
-$0 |
26.8 |
na |
na |
na |
na |
| LA JOLLA PHARMACEUTICAL COMPANY |
$2.43 |
47% |
-15% |
$149 |
$55 |
$2 |
$96 |
$0.7 |
-$34 |
1.6 |
Jun-94 |
0.5 |
$5.00 |
$43 |
| PROTEIN DESIGN LABS |
$19.13 |
69% |
31% |
$1,801 |
$465 |
$259 |
$1,596 |
$2.9 |
-$50 |
9.2 |
Jan-92 |
2.6 |
$7.50 |
$191 |
| TANOX |
$19.07 |
84% |
19% |
$838 |
$135 |
$5 |
$708 |
$6.0 |
na |
na |
Apr-00 |
0.7 |
$28.50 |
$1,193 |
| Autoimmune Average |
|
71% |
34% |
$711 |
$157 |
|
$639 |
$4.6 |
-$73 |
9.7 |
|
1.6 |
|
|
| Autoimmune Median |
|
71% |
19% |
$410 |
$117 |
|
$302 |
$2.9 |
-$34 |
3.7 |
|
1.4 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/30/04 Close |
% of 52wk High |
% change from 6/27/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ALLOS THERAPEUTICS |
$2.25 |
38% |
-20% |
$70 |
$42 |
$0 |
$28 |
$0.5 |
-$20 |
2.1 |
Mar-00 |
0.1 |
$18.00 |
$604 |
| ANTIGENICS |
$8.56 |
55% |
-31% |
$386 |
$138 |
$8 |
$256 |
$1.2 |
-$69 |
2.0 |
Feb-00 |
0.5 |
$18.00 |
$429 |
| APHTON CORP. |
$4.00 |
40% |
-46% |
$151 |
$63 |
$11 |
$99 |
$1.9 |
-$25 |
2.5 |
na |
na |
na |
na |
| ARIAD PHARMACEUTICALS |
$7.49 |
55% |
93% |
$392 |
$91 |
$8 |
$309 |
$5.9 |
-$25 |
3.7 |
May-94 |
0.9 |
$8.00 |
$124 |
| AVI BIOPHARMA |
$2.40 |
38% |
-60% |
$87 |
$37 |
$0 |
$50 |
$0.5 |
-$30 |
1.2 |
Jun-97 |
0.3 |
$9.00 |
$103 |
| BIOMIRA |
$1.29 |
51% |
-14% |
$94 |
$27 |
$0 |
$67 |
$0.4 |
-$15 |
1.8 |
Jun-87 |
0.3 |
$4.40 |
$43 |
| BOSTON LIFE SCIENCES |
$1.03 |
49% |
-32% |
$35 |
$10 |
$4 |
$29 |
$2.4 |
-$11 |
0.9 |
na |
na |
na |
na |
| CANCERVAX |
$7.61 |
57% |
na |
$203 |
$93 |
$4 |
$115 |
$0.8 |
-$51 |
1.8 |
Oct-03 |
0.6 |
$12.00 |
$308 |
| CELGENE CORP. |
$57.26 |
94% |
83% |
$4,685 |
$714 |
$400 |
$4,371 |
$6.4 |
na |
na |
Jul-87 |
15.6 |
$3.66 |
$55 |
| CELL THERAPEUTICS |
$7.37 |
54% |
-26% |
$371 |
$140 |
$192 |
$423 |
$1.1 |
-$546 |
0.3 |
Mar-97 |
0.7 |
$10.00 |
$166 |
| CORIXA CORP. |
$4.67 |
47% |
-35% |
$260 |
$133 |
$153 |
$280 |
$0.8 |
-$84 |
1.6 |
Oct-97 |
0.4 |
$13.00 |
$152 |
| CYTOGEN CORP. |
$15.90 |
96% |
110% |
$247 |
$26 |
$0 |
$220 |
$3.6 |
-$17 |
1.5 |
Jun-86 |
1.2 |
$13.00 |
$148 |
| CYTOKINETICS |
$14.85 |
83% |
na |
$507 |
$28 |
$2 |
$481 |
$2.9 |
-$24 |
1.2 |
Apr-04 |
1.1 |
$13.00 |
$444 |
| DENDREON CORP. |
$12.25 |
73% |
88% |
$708 |
$205 |
$3 |
$505 |
$3.5 |
-$52 |
3.9 |
Jun-00 |
1.2 |
$10.00 |
$210 |
| DUSA PHARMACEUTICALS |
$9.50 |
64% |
280% |
$159 |
$56 |
$2 |
$104 |
$2.1 |
-$18 |
3.2 |
Jan-92 |
1.6 |
$6.00 |
$30 |
| ENTREMED |
$2.01 |
34% |
-52% |
$76 |
$31 |
$0 |
$45 |
$1.0 |
-$20 |
1.6 |
Jun-96 |
0.1 |
$15.00 |
$182 |
| EXEGENICS |
$0.73 |
55% |
38% |
$12 |
$10 |
$0 |
$2 |
$0.2 |
-$3 |
3.6 |
na |
na |
na |
na |
| GENAERA CORP. |
$4.20 |
64% |
127% |
$220 |
$30 |
$0 |
$190 |
$8.3 |
-$18 |
1.7 |
Dec-91 |
0.5 |
$9.00 |
$62 |
| GENITOPE |
$9.87 |
68% |
na |
$168 |
$83 |
$0 |
$84 |
$0.9 |
-$27 |
3.1 |
Oct-03 |
1.1 |
$9.00 |
$145 |
| GENTA ORPORATED |
$2.50 |
14% |
-81% |
$194 |
$69 |
$45 |
$171 |
$1.1 |
-$50 |
1.4 |
Dec-91 |
0.0 |
$100.00 |
$123 |
| GERON CORP. |
$8.05 |
48% |
13% |
$363 |
$104 |
$5 |
$265 |
$5.0 |
-$207 |
0.5 |
Jul-96 |
1.0 |
$8.00 |
$77 |
| GTX |
$10.41 |
65% |
na |
$257 |
$82 |
$0 |
$175 |
$4.2 |
-$23 |
3.5 |
Feb-04 |
0.7 |
$14.50 |
$358 |
| ILEX ONCOLOGY |
$24.99 |
96% |
20% |
$976 |
$145 |
$39 |
$870 |
$4.0 |
-$74 |
2.0 |
Feb-97 |
2.1 |
$12.00 |
$143 |
| IMCLONE SYSTEMS |
$85.79 |
100% |
158% |
$6,549 |
$309 |
$240 |
$6,480 |
$15.3 |
na |
na |
Nov-91 |
12.3 |
$7.00 |
$107 |
| IMMUNOGEN |
$6.07 |
49% |
42% |
$247 |
$103 |
$0 |
$144 |
$1.2 |
-$3 |
32.1 |
Nov-89 |
0.6 |
$10.00 |
$60 |
| IMMUNOMEDICS |
$4.87 |
50% |
-22% |
$243 |
$22 |
$17 |
$238 |
$2.2 |
-$22 |
1.0 |
Oct-83 |
3.9 |
$1.25 |
$25 |
| MAXIM PHARMACEUTICALS |
$9.65 |
91% |
65% |
$273 |
$73 |
$1 |
$202 |
$2.1 |
-$36 |
2.0 |
Jul-96 |
1.3 |
$7.50 |
$50 |
| MEDAREX |
$7.29 |
65% |
12% |
$577 |
$342 |
$289 |
$524 |
$1.2 |
-$124 |
2.8 |
Jun-91 |
2.4 |
$3.00 |
$31 |
| NEOPHARM |
$10.33 |
46% |
-29% |
$240 |
$103 |
$0 |
$137 |
$1.3 |
-$57 |
1.8 |
Jan-96 |
3.2 |
$3.18 |
$28 |
| NEORX CORP. |
$2.49 |
35% |
-26% |
$76 |
$32 |
$4 |
$48 |
$1.2 |
-$20 |
1.7 |
Aug-88 |
0.1 |
$28.00 |
$102 |
| OSI PHARMACEUTICALS |
$70.44 |
71% |
115% |
$2,870 |
$334 |
$310 |
$2,846 |
$5.9 |
-$199 |
1.7 |
Apr-86 |
11.7 |
$6.00 |
$53 |
| OXIGENE |
$6.30 |
42% |
-38% |
$105 |
$40 |
$0 |
$66 |
$6.0 |
-$8 |
4.7 |
Oct-93 |
1.1 |
$6.00 |
$28 |
| PHARMION |
$48.92 |
98% |
na |
$1,237 |
$81 |
$0 |
$1,156 |
$19.6 |
-$39 |
2.1 |
Nov-03 |
3.5 |
$14.00 |
$358 |
| PRAECIS PHARMACEUTICALS ORPORATED |
$3.80 |
48% |
-19% |
$199 |
$127 |
$32 |
$104 |
$0.6 |
-$62 |
2.1 |
Apr-00 |
0.4 |
$10.00 |
$400 |
| PROGENICS PHARMACEUTICALS |
$16.85 |
72% |
20% |
$285 |
$47 |
$0 |
$238 |
$2.1 |
-$41 |
1.1 |
Nov-97 |
2.1 |
$8.00 |
$70 |
| QLT |
$20.04 |
65% |
56% |
$1,394 |
$537 |
$173 |
$1,030 |
$3.1 |
na |
na |
Sep-86 |
18.6 |
$1.08 |
$22 |
| SCICLONE PHARMACEUTICALS |
$5.07 |
52% |
-42% |
$226 |
$60 |
$6 |
$171 |
$1.6 |
-$12 |
4.9 |
Mar-92 |
0.7 |
$7.45 |
$63 |
| SEATTLE GENETICS |
$7.03 |
64% |
43% |
$283 |
$51 |
$0 |
$231 |
$2.1 |
-$27 |
1.9 |
Mar-01 |
1.0 |
$7.00 |
$207 |
| SPECTRUM PHARMACEUTICALS |
$6.25 |
60% |
32% |
$84 |
$25 |
$0 |
$59 |
$3.7 |
-$9 |
2.8 |
na |
na |
na |
na |
| SUPERGEN |
$6.45 |
46% |
21% |
$286 |
$47 |
$6 |
$245 |
$2.1 |
-$75 |
0.6 |
Mar-96 |
1.1 |
$6.00 |
$21 |
| TAPESTRY PHARMACEUTICALS |
$1.76 |
53% |
5% |
$58 |
$48 |
$6 |
$17 |
$0.3 |
-$20 |
2.4 |
Apr-94 |
0.4 |
$5.00 |
$41 |
| VERNALIS |
$2.27 |
70% |
-1% |
$39 |
$67 |
$0 |
-$28 |
-$0.3 |
-$26 |
2.6 |
May-96 |
0.3 |
$7.20 |
$178 |
| XCYTE THERAPIES |
$4.40 |
52% |
na |
$65 |
$41 |
$2 |
$26 |
$0.4 |
-$73 |
0.6 |
Mar-04 |
0.6 |
$8.00 |
$119 |
| XENOVA PLC |
$2.06 |
73% |
2% |
$41 |
$26 |
$0 |
$15 |
$0.1 |
-$33 |
0.8 |
Jul-94 |
0.1 |
$16.00 |
$90 |
| Cancer Average |
|
60% |
22% |
$591 |
$111 |
|
$525 |
$3.0 |
-$56 |
2.8 |
|
2.4 |
|
|
| Cancer Median |
|
55% |
12% |
$240 |
$63 |
|
$171 |
$1.9 |
-$26 |
1.9 |
|
1.0 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/30/04 Close |
% of 52wk High |
% change from 6/27/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| CORGENTECH |
$16.12 |
74% |
na |
$442 |
$154 |
$1 |
$288 |
$4.0 |
-$26 |
5.8 |
Feb-04 |
1.0 |
$16.00 |
$438 |
| CV THERAPEUTICS |
$16.76 |
46% |
-44% |
$528 |
$446 |
$297 |
$378 |
$1.4 |
-$125 |
3.6 |
Nov-96 |
2.1 |
$8.00 |
$48 |
| ENCYSIVE PHARMACEUTICALS |
$8.50 |
72% |
80% |
$449 |
$70 |
$2 |
$380 |
$4.1 |
-$44 |
1.6 |
Dec-93 |
1.3 |
$6.75 |
$88 |
| MEDICINES COMPANY |
$30.51 |
84% |
54% |
$1,455 |
$129 |
$0 |
$1,326 |
$7.0 |
na |
na |
Sep-00 |
1.9 |
$16.00 |
$506 |
| MYOGEN |
$7.74 |
40% |
na |
$205 |
$95 |
$3 |
$113 |
$2.0 |
-$64 |
1.5 |
Oct-03 |
0.6 |
$14.00 |
$358 |
| NITROMED |
$6.06 |
52% |
na |
$155 |
$91 |
$0 |
$65 |
$1.6 |
-$18 |
4.9 |
Nov-03 |
0.6 |
$11.00 |
$264 |
| QUESTCOR PHARMACEUTICALS |
$0.85 |
73% |
-13% |
$43 |
$7 |
$4 |
$40 |
$0.8 |
na |
na |
na |
na |
na |
na |
| Cardiovascular Average |
|
63% |
19% |
$468 |
$142 |
|
$370 |
$3.0 |
-$56 |
3.5 |
|
1.2 |
|
|
| Cardiovascular Median |
|
73% |
54% |
$323 |
$93 |
|
$201 |
$1.8 |
-$35 |
2.6 |
|
1.0 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/30/04 Close |
% of 52wk High |
% change from 6/27/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ACCELRYS |
$9.86 |
42% |
54% |
$240 |
$147 |
$0 |
$93 |
$0.1 |
-$107 |
1.4 |
Dec-95 |
0.6 |
$16.00 |
$158 |
| ALBANY MOLECULAR RESEARCH |
$12.93 |
74% |
-16% |
$410 |
$133 |
$58 |
$335 |
$0.4 |
na |
na |
Feb-99 |
1.3 |
$10.00 |
$280 |
| ARGONAUT TECHNOLOGIES |
$1.34 |
50% |
3% |
$27 |
$12 |
$0 |
$16 |
$0.1 |
-$10 |
1.2 |
Jul-00 |
0.1 |
$15.00 |
$253 |
| ARQULE |
$5.27 |
66% |
33% |
$152 |
$61 |
$6 |
$97 |
$0.4 |
-$21 |
2.9 |
Oct-96 |
0.4 |
$12.00 |
$114 |
| ARRAY BIOPHARMA |
$7.95 |
67% |
144% |
$229 |
$38 |
$0 |
$191 |
$0.8 |
-$39 |
1.0 |
Nov-01 |
1.1 |
$7.50 |
$168 |
| BIOCRYST PHARMACEUTICALS |
$6.90 |
61% |
80% |
$148 |
$29 |
$0 |
$119 |
$2.6 |
-$22 |
1.3 |
Mar-94 |
1.1 |
$6.50 |
$47 |
| DISCOVERY PARTNERS INTERNATIONAL |
$5.10 |
76% |
19% |
$126 |
$74 |
$0 |
$51 |
$0.3 |
na |
na |
Jul-00 |
0.3 |
$18.00 |
$428 |
| KOSAN BIOSCIENCES ORPORATED |
$7.90 |
53% |
32% |
$228 |
$76 |
$4 |
$157 |
$1.2 |
-$16 |
4.6 |
Oct-00 |
0.6 |
$14.00 |
$341 |
| SYMYX TECHNOLOGIES |
$24.12 |
80% |
46% |
$771 |
$146 |
$0 |
$625 |
$2.7 |
na |
na |
Nov-99 |
1.7 |
$14.00 |
$398 |
| VERTEX PHARMACEUTICALS ORPORATED |
$10.84 |
65% |
-30% |
$854 |
$526 |
$315 |
$644 |
$0.9 |
-$162 |
3.3 |
Jul-91 |
2.4 |
$4.50 |
$85 |
| Chemistry Average |
|
63% |
37% |
$319 |
$124 |
|
$233 |
$0.9 |
-$54 |
2.2 |
|
1.0 |
|
|
| Chemistry Median |
|
66% |
33% |
$228 |
$74 |
|
$119 |
$0.8 |
-$22 |
1.3 |
|
1.0 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/30/04 Close |
% of 52wk High |
% change from 6/27/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ACADIA PHARMACEUTICALS |
$6.20 |
83% |
na |
$104 |
$57 |
$1 |
$48 |
$0.5 |
-$26 |
2.2 |
May-04 |
0.9 |
$7.00 |
$117 |
| ADOLOR CORP. |
$12.68 |
57% |
4% |
$492 |
$197 |
$0 |
$295 |
$2.3 |
-$41 |
4.8 |
Nov-00 |
0.8 |
$15.00 |
$407 |
| CEPHALON |
$54.00 |
89% |
31% |
$3,029 |
$1,225 |
$1,412 |
$3,216 |
$2.0 |
na |
na |
Apr-91 |
3.0 |
$18.00 |
$155 |
| CORCEPT THERAPEUTICS |
$7.72 |
61% |
na |
$175 |
$12 |
$0 |
$163 |
$23.3 |
-$10 |
1.1 |
Apr-04 |
0.6 |
$12.00 |
$272 |
| DOV PHARMACEUTICAL |
$13.96 |
69% |
27% |
$253 |
$52 |
$15 |
$216 |
$6.0 |
-$31 |
1.7 |
Apr-02 |
1.1 |
$13.00 |
$188 |
| GUILFORD PHARMACEUTICALS |
$4.75 |
49% |
7% |
$161 |
$62 |
$92 |
$191 |
$0.7 |
-$72 |
0.9 |
Jun-94 |
0.9 |
$5.33 |
$30 |
| INDEVUS PHARMACEUTICALS |
$6.15 |
60% |
-4% |
$293 |
$62 |
$72 |
$303 |
$11.2 |
-$46 |
1.4 |
Mar-90 |
3.1 |
$2.00 |
$31 |
| MEMORY PHARMACEUTICALS |
$9.10 |
83% |
na |
$184 |
$24 |
$0 |
$160 |
$2.1 |
-$19 |
1.2 |
Apr-04 |
1.3 |
$7.00 |
$141 |
| NEUROBIOLOGICAL TECHNOLOGIES |
$3.72 |
52% |
0% |
$89 |
$21 |
$0 |
$68 |
$6.2 |
na |
na |
Feb-94 |
0.5 |
$8.00 |
$30 |
| NEUROCRINE BIOSCIENCES |
$51.85 |
74% |
1% |
$1,885 |
$377 |
$47 |
$1,555 |
$4.9 |
-$50 |
7.6 |
May-96 |
4.9 |
$10.50 |
$172 |
| NYMOX PHARMACEUTICAL CORP. |
$3.76 |
70% |
17% |
$90 |
$1 |
$1 |
$90 |
$4.3 |
-$4 |
0.2 |
na |
na |
na |
na |
| PAIN THERAPEUTICS |
$8.06 |
82% |
37% |
$286 |
$71 |
$0 |
$215 |
$7.2 |
-$41 |
1.7 |
Jul-00 |
0.7 |
$12.00 |
$319 |
| PHARMOS CORP. |
$4.11 |
82% |
104% |
$361 |
$64 |
$16 |
$314 |
$5.9 |
-$24 |
2.7 |
Jul-83 |
0.2 |
$20.00 |
$16 |
| RENOVIS |
$9.16 |
52% |
na |
$225 |
$113 |
$3 |
$115 |
$1.6 |
-$35 |
3.3 |
Feb-04 |
0.8 |
$12.00 |
$295 |
| STEMCELLS |
$1.53 |
49% |
-4% |
$63 |
$10 |
$2 |
$54 |
$1.9 |
-$11 |
0.9 |
Mar-92 |
0.1 |
$11.00 |
$82 |
| TITAN PHARMACEUTICALS |
$2.69 |
46% |
28% |
$86 |
$57 |
$0 |
$29 |
$0.5 |
-$26 |
2.2 |
Jan-96 |
0.5 |
$5.00 |
$66 |
| CNS Average |
|
66% |
21% |
$486 |
$150 |
|
$440 |
$5.0 |
-$31 |
2.3 |
|
1.3 |
|
|
| CNS Median |
|
69% |
17% |
$184 |
$57 |
|
$163 |
$2.3 |
-$26 |
1.7 |
|
0.9 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/30/04 Close |
% of 52wk High |
% change from 6/27/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ABGENIX |
$11.72 |
60% |
7% |
$1,040 |
$317 |
$249 |
$971 |
$2.4 |
-$166 |
1.9 |
Jul-98 |
5.9 |
$2.00 |
$86 |
| ACUSPHERE |
$6.40 |
39% |
na |
$92 |
$48 |
$0 |
$44 |
$0.8 |
-$28 |
1.7 |
Oct-03 |
0.5 |
$14.00 |
$200 |
| AEROGEN |
$3.10 |
48% |
17% |
$15 |
$5 |
$0 |
$10 |
$0.1 |
-$18 |
0.3 |
Nov-00 |
0.3 |
$12.00 |
$233 |
| ALKERMES |
$13.60 |
79% |
23% |
$1,223 |
$146 |
$127 |
$1,204 |
$2.8 |
-$99 |
1.5 |
Jul-91 |
2.7 |
$5.00 |
$70 |
| ANDRX CORP. |
$27.93 |
90% |
41% |
$2,030 |
$332 |
$12 |
$1,711 |
$0.8 |
na |
na |
Jun-96 |
9.3 |
$3.00 |
$155 |
| ARADIGM CORP. |
$0.90 |
31% |
-51% |
$57 |
$18 |
$0 |
$39 |
$0.2 |
-$31 |
0.6 |
Jun-96 |
0.1 |
$11.00 |
$114 |
| ATRIX LABORATORIES |
$34.28 |
98% |
55% |
$750 |
$106 |
$0 |
$645 |
$4.1 |
na |
na |
na |
na |
na |
na |
| BIODELIVERY SCIENCES INTERNATIONAL |
$3.00 |
60% |
-25% |
$21 |
$2 |
$1 |
$20 |
$1.1 |
-$4 |
0.4 |
na |
na |
na |
na |
| CIMA LABS |
$33.73 |
100% |
22% |
$495 |
$75 |
$0 |
$420 |
$1.5 |
na |
na |
Jul-94 |
3.7 |
$9.00 |
$66 |
| DEPOMED |
$4.94 |
55% |
-1% |
$171 |
$38 |
$10 |
$143 |
$1.9 |
-$27 |
1.4 |
Nov-97 |
0.8 |
$6.10 |
$33 |
| DOR BIOPHARMA |
$0.55 |
35% |
-39% |
$23 |
$6 |
$0 |
$17 |
$4.3 |
-$5 |
1.3 |
na |
na |
na |
na |
| DURECT CORP. |
$3.46 |
81% |
45% |
$177 |
$59 |
$62 |
$180 |
$1.7 |
-$24 |
2.5 |
Sep-00 |
0.3 |
$12.00 |
$557 |
| EMISPHERE TECHNOLOGIES |
$4.10 |
45% |
12% |
$75 |
$32 |
$40 |
$84 |
$0.7 |
-$40 |
0.8 |
Feb-89 |
0.8 |
$5.00 |
$15 |
| ENZON PHARMACEUTICALS |
$12.76 |
69% |
-2% |
$560 |
$114 |
$400 |
$846 |
$2.7 |
na |
na |
Feb-84 |
8.5 |
$1.50 |
$12 |
| FLAMEL TECHNOLOGIES SA |
$24.63 |
56% |
77% |
$527 |
$111 |
$2 |
$418 |
$2.8 |
na |
na |
na |
na |
na |
na |
| GENEREX BIOTECHNOLOGY CORP. |
$1.45 |
59% |
-15% |
$46 |
$8 |
$2 |
$40 |
$1.5 |
-$20 |
0.4 |
na |
na |
na |
na |
| GENETRONICS BIOMEDICAL CORP. |
$1.30 |
67% |
76% |
$91 |
$13 |
$0 |
$78 |
$3.9 |
-$6 |
2.1 |
na |
na |
na |
na |
| KOS PHARMACEUTICALS |
$32.97 |
55% |
41% |
$1,229 |
$108 |
$30 |
$1,151 |
$1.3 |
na |
na |
Mar-97 |
2.2 |
$15.00 |
$233 |
| MACROCHEM CORP. |
$1.45 |
77% |
36% |
$56 |
$12 |
$0 |
$44 |
$2.7 |
-$9 |
1.4 |
Feb-85 |
0.5 |
$3.00 |
$13 |
| MEDICIS PHARMACEUTICAL CORP. |
$39.95 |
88% |
-29% |
$2,237 |
$628 |
$471 |
$2,080 |
$6.7 |
na |
na |
na |
na |
na |
na |
| NASTECH PHARMACEUTICAL COMPANY |
$10.20 |
68% |
-1% |
$122 |
$20 |
$11 |
$113 |
$1.4 |
-$30 |
0.7 |
na |
na |
na |
na |
| NEKTAR THERAPEUTICS |
$19.96 |
80% |
121% |
$1,667 |
$486 |
$215 |
$1,396 |
$2.1 |
-$160 |
3.0 |
May-94 |
5.3 |
$3.75 |
$65 |
| NOVAVAX |
$5.39 |
63% |
-2% |
$187 |
$23 |
$42 |
$206 |
$1.8 |
-$21 |
1.1 |
na |
na |
na |
na |
| NOVEN PHARMACEUTICALS |
$22.02 |
85% |
114% |
$515 |
$113 |
$0 |
$403 |
$1.3 |
na |
na |
May-88 |
40.0 |
$0.55 |
$5 |
| SEPRACOR |
$52.90 |
98% |
188% |
$4,528 |
$502 |
$1,192 |
$5,218 |
$5.3 |
-$202 |
2.5 |
Sep-91 |
10.6 |
$5.00 |
$168 |
| Delivery Average |
|
67% |
30% |
$717 |
$133 |
|
$699 |
$2.2 |
-$52 |
1.4 |
|
5.7 |
|
|
| Delivery Median |
|
68% |
22% |
$182 |
$54 |
|
$193 |
$1.7 |
-$25 |
1.3 |
|
2.2 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/30/04 Close |
% of 52wk High |
% change from 6/27/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ADVANCED MAGNETICS |
$15.13 |
99% |
47% |
$118 |
$18 |
$0 |
$100 |
$4.6 |
-$2 |
7.4 |
na |
na |
na |
na |
| BIOSITE ORPORATED |
$45.09 |
78% |
-8% |
$706 |
$75 |
$20 |
$651 |
$0.8 |
na |
na |
Feb-97 |
3.8 |
$12.00 |
$149 |
| CHOLESTECH CORP. |
$8.15 |
79% |
-20% |
$116 |
$18 |
$0 |
$98 |
$0.5 |
na |
na |
Jun-92 |
1.6 |
$5.00 |
$32 |
| DIAGNOSTIC PRODUCTS CORP. |
$36.53 |
74% |
-12% |
$722 |
$77 |
$17 |
$662 |
$0.3 |
na |
na |
Jun-82 |
9.1 |
$4.00 |
$43 |
| DIGENE CORP. |
$9.59 |
69% |
-66% |
$448 |
$49 |
$3 |
$402 |
$1.4 |
na |
na |
May-96 |
0.8 |
$11.50 |
$128 |
| ENZO BIOCHEM |
$15.00 |
66% |
-32% |
$463 |
$80 |
$0 |
$383 |
$1.8 |
-$2 |
40.0 |
Jun-80 |
17.2 |
$0.87 |
$8 |
| EPIX MEDICAL |
$21.10 |
80% |
53% |
$481 |
$76 |
$0 |
$405 |
$4.7 |
-$16 |
4.8 |
Feb-97 |
3.0 |
$7.00 |
$59 |
| EXACT SCIENCES CORP. |
$6.16 |
34% |
-44% |
$161 |
$67 |
$0 |
$94 |
$1.1 |
-$21 |
3.2 |
Jan-01 |
0.4 |
$14.00 |
$261 |
| GEN-PROBE ORPORATED |
$47.32 |
88% |
128% |
$2,328 |
$198 |
$0 |
$2,130 |
$2.9 |
na |
na |
Sep-87 |
6.8 |
$7.00 |
$103 |
| IDEXX LABORATORIES |
$62.94 |
91% |
84% |
$2,186 |
$230 |
$1 |
$1,958 |
$0.8 |
na |
na |
Jun-91 |
16.8 |
$3.75 |
$76 |
| IMMUCOR |
$32.55 |
98% |
50% |
$647 |
$13 |
$14 |
$648 |
$1.8 |
na |
na |
na |
na |
na |
na |
| IMMUNICON |
$7.85 |
75% |
na |
$173 |
$25 |
$7 |
$155 |
$1.5 |
-$26 |
1.0 |
Apr-04 |
1.0 |
$8.00 |
$176 |
| LUMINEX CORP. |
$10.06 |
75% |
91% |
$309 |
$38 |
$0 |
$271 |
$2.1 |
-$0 |
94.8 |
Mar-00 |
0.6 |
$17.00 |
$450 |
| MARTEK BIOSCIENCES CORP. |
$56.17 |
77% |
29% |
$1,644 |
$60 |
$82 |
$1,665 |
$4.3 |
na |
na |
Nov-93 |
8.0 |
$7.00 |
$54 |
| MATRITECH |
$1.30 |
49% |
-45% |
$54 |
$12 |
$2 |
$44 |
$0.7 |
-$11 |
1.1 |
Jul-92 |
0.3 |
$5.00 |
$22 |
| MERIDIAN BIOSCIENCE |
$11.08 |
86% |
21% |
$165 |
$3 |
$22 |
$184 |
$0.8 |
na |
na |
na |
na |
na |
na |
| ORASURE TECHNOLOGIES |
$9.73 |
81% |
25% |
$433 |
$65 |
$3 |
$371 |
$2.2 |
-$1 |
81.1 |
na |
na |
na |
na |
| QUIDEL CORP. |
$5.89 |
42% |
0% |
$186 |
$40 |
$10 |
$156 |
$0.6 |
na |
na |
Aug-81 |
0.6 |
$10.00 |
$19 |
| SONUS PHARMACEUTICALS |
$4.75 |
54% |
26% |
$86 |
$17 |
$0 |
$70 |
$1.7 |
-$14 |
1.2 |
Oct-95 |
0.7 |
$7.00 |
$60 |
| STRATAGENE |
$8.40 |
70% |
73% |
$184 |
$8 |
$0 |
$176 |
$1.2 |
na |
na |
na |
na |
na |
na |
| TRINITY BIOTECH PLC |
$3.37 |
50% |
11% |
$155 |
$23 |
$22 |
$154 |
$0.3 |
na |
na |
na |
na |
na |
na |
| Diagnostic/imag. Average |
|
72% |
21% |
$560 |
$57 |
|
$513 |
$1.7 |
-$10 |
26.1 |
|
4.7 |
|
|
| Diagnostic/imag. Median |
|
76% |
25% |
$248 |
$39 |
|
$228 |
$1.3 |
-$7 |
4.0 |
|
1.3 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/30/04 Close |
% of 52wk High |
% change from 6/27/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| AASTROM BIOSCIENCES |
$0.90 |
49% |
-15% |
$73 |
$11 |
$0 |
$62 |
$1.4 |
-$10 |
1.1 |
Feb-97 |
0.1 |
$7.00 |
$88 |
| AVIGEN |
$3.37 |
42% |
-4% |
$69 |
$82 |
$9 |
-$5 |
-$0.0 |
-$29 |
2.8 |
May-96 |
0.4 |
$8.00 |
$58 |
| CELL GENESYS |
$10.39 |
64% |
13% |
$464 |
$230 |
$148 |
$382 |
$1.4 |
-$84 |
2.7 |
Jan-93 |
0.9 |
$11.00 |
$120 |
| CORAUTUS GENETICS |
$5.80 |
75% |
90% |
$72 |
$15 |
$4 |
$61 |
$2.0 |
-$10 |
1.4 |
na |
na |
na |
na |
| GENVEC |
$3.07 |
68% |
54% |
$170 |
$25 |
$6 |
$151 |
$1.7 |
-$23 |
1.1 |
Dec-00 |
0.3 |
$9.50 |
$186 |
| INTROGEN THERAPEUTICS |
$4.27 |
38% |
-23% |
$114 |
$31 |
$7 |
$90 |
$1.2 |
-$22 |
1.4 |
Oct-00 |
0.5 |
$8.00 |
$167 |
| SIRNA THERAPEUTICS |
$2.94 |
32% |
-66% |
$93 |
$30 |
$3 |
$66 |
$0.9 |
-$24 |
1.3 |
Apr-96 |
0.3 |
$10.00 |
$59 |
| TARGETED GENETICS CORP. |
$1.59 |
48% |
-17% |
$130 |
$42 |
$12 |
$101 |
$1.1 |
-$20 |
2.1 |
May-94 |
0.3 |
$6.00 |
$54 |
| TRANSGENE SA |
$3.02 |
69% |
26% |
$91 |
$45 |
$3 |
$49 |
$0.3 |
na |
na |
Mar-98 |
0.1 |
$43.50 |
$212 |
| TRANSKARYOTIC THERAPIES |
$14.96 |
79% |
36% |
$518 |
$171 |
$0 |
$347 |
$1.1 |
-$57 |
3.0 |
Oct-96 |
1.0 |
$15.00 |
$234 |
| VALENTIS |
$6.96 |
82% |
77% |
$74 |
$6 |
$0 |
$69 |
$3.6 |
-$14 |
0.4 |
Sep-97 |
0.6 |
$12.00 |
$161 |
| VICAL ORPORATED |
$5.79 |
71% |
35% |
$136 |
$94 |
$12 |
$54 |
$0.3 |
-$36 |
2.6 |
Mar-93 |
1.2 |
$5.00 |
$52 |
| Gene therapy Average |
|
60% |
17% |
$167 |
$65 |
|
$119 |
$1.3 |
-$30 |
1.8 |
|
0.5 |
|
|
| Gene therapy Median |
|
68% |
26% |
$93 |
$31 |
|
$66 |
$1.1 |
-$22 |
1.4 |
|
0.5 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/30/04 Close |
% of 52wk High |
% change from 6/27/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ADVANCIS |
$6.73 |
65% |
na |
$153 |
$58 |
$3 |
$99 |
$1.2 |
-$42 |
1.4 |
Oct-03 |
0.7 |
$10.00 |
$224 |
| ANADYS PHARMACEUTICALS |
$7.10 |
82% |
na |
$158 |
$52 |
$2 |
$109 |
$1.3 |
-$30 |
1.8 |
Mar-04 |
1.0 |
$7.00 |
$156 |
| AVANT IMMUNOTHERAPEUTICS |
$2.66 |
68% |
2% |
$198 |
$41 |
$0 |
$156 |
$2.7 |
-$8 |
5.4 |
May-86 |
0.7 |
$4.00 |
$38 |
| CUBIST PHARMACEUTICALS |
$11.10 |
69% |
5% |
$446 |
$87 |
$197 |
$557 |
$1.9 |
-$93 |
0.9 |
Oct-96 |
1.9 |
$6.00 |
$55 |
| DYNAVAX TECHNOLOGIES |
$6.66 |
67% |
na |
$164 |
$80 |
$0 |
$84 |
$1.9 |
-$16 |
5.1 |
Feb-04 |
0.9 |
$7.50 |
$185 |
| EPIMMUNE |
$1.70 |
40% |
29% |
$27 |
$6 |
$0 |
$22 |
$0.6 |
-$2 |
2.8 |
Nov-91 |
0.0 |
$91.00 |
$167 |
| GENELABS TECHNOLOGIES |
$2.31 |
71% |
48% |
$203 |
$27 |
$0 |
$176 |
$2.4 |
-$19 |
1.5 |
Jun-91 |
0.3 |
$9.13 |
$160 |
| IMMUNE RESPONSE CORP. |
$1.22 |
35% |
-62% |
$59 |
$9 |
$4 |
$54 |
$1.2 |
-$58 |
0.2 |
May-90 |
0.0 |
$28.00 |
$77 |
| INHIBITEX |
$7.21 |
93% |
na |
$126 |
$58 |
$2 |
$70 |
$1.2 |
-$26 |
2.3 |
Jun-04 |
1.0 |
$7.00 |
$122 |
| INTERMUNE |
$15.42 |
62% |
2% |
$493 |
$315 |
$267 |
$446 |
$1.7 |
-$47 |
6.7 |
Mar-00 |
0.8 |
$20.00 |
$433 |
| INTRABIOTICS PHARMACEUTICALS - |
$3.89 |
20% |
-11% |
$21 |
$62 |
$0 |
-$41 |
-$4.1 |
-$25 |
2.5 |
Apr-00 |
0.3 |
$15.00 |
$419 |
| MEDIMMUNE |
$23.39 |
57% |
-35% |
$5,818 |
$634 |
$507 |
$5,691 |
$3.4 |
na |
na |
May-91 |
15.2 |
$1.54 |
$114 |
| NABI BIOPHARMACEUTICALS |
$14.22 |
79% |
109% |
$819 |
$126 |
$24 |
$716 |
$1.0 |
-$19 |
6.5 |
na |
na |
na |
na |
| SIGA TECHNOLOGIES |
$1.40 |
47% |
-14% |
$33 |
$0 |
$0 |
$33 |
$1.9 |
na |
na |
Sep-97 |
0.3 |
$5.00 |
$32 |
| TRIMERIS |
$14.43 |
26% |
-69% |
$312 |
$81 |
$0 |
$231 |
$2.3 |
-$40 |
2.0 |
Oct-97 |
1.2 |
$12.00 |
$120 |
| VAXGEN |
$14.16 |
78% |
177% |
$355 |
$34 |
$0 |
$321 |
$2.7 |
-$37 |
0.9 |
Jul-99 |
1.1 |
$13.00 |
$146 |
| VICURON PHARMACEUTICALS |
$12.56 |
51% |
-12% |
$686 |
$149 |
$9 |
$546 |
$14.7 |
-$94 |
1.6 |
Sep-00 |
1.1 |
$11.00 |
$249 |
| VION PHARMACEUTICALS |
$4.16 |
76% |
157% |
$230 |
$52 |
$0 |
$179 |
$6.2 |
-$13 |
3.9 |
Aug-95 |
1.0 |
$4.00 |
$32 |
| VIROLOGIC |
$2.45 |
56% |
87% |
$131 |
$11 |
$0 |
$121 |
$0.6 |
-$5 |
2.2 |
May-00 |
0.4 |
$7.00 |
$137 |
| VIROPHARMA ORPORATED |
$1.79 |
48% |
-33% |
$48 |
$111 |
$128 |
$65 |
$0.7 |
-$66 |
1.7 |
Nov-96 |
0.3 |
$7.00 |
$65 |
| XOMA LTD |
$4.48 |
42% |
-22% |
$378 |
$80 |
$56 |
$354 |
$1.6 |
-$81 |
1.0 |
Jun-86 |
0.3 |
$16.00 |
$140 |
| Infection Average |
|
59% |
21% |
$517 |
$99 |
|
$476 |
$2.2 |
-$38 |
2.6 |
|
1.4 |
|
|
| Infection Median |
|
64% |
2% |
$181 |
$58 |
|
$139 |
$1.6 |
-$28 |
1.9 |
|
0.8 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/30/04 Close |
% of 52wk High |
% change from 6/27/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| AMYLIN PHARMACEUTICALS |
$22.80 |
74% |
2% |
$2,142 |
$227 |
$177 |
$2,092 |
$9.3 |
-$149 |
1.5 |
Jan-92 |
1.6 |
$14.00 |
$240 |
| BIOMARIN PHARMACEUTICAL |
$6.00 |
55% |
-36% |
$386 |
$208 |
$125 |
$303 |
$1.1 |
-$80 |
2.6 |
Aug-99 |
0.5 |
$13.00 |
$449 |
| INSMED |
$2.24 |
52% |
-18% |
$86 |
$25 |
$0 |
$61 |
$3.0 |
-$19 |
1.3 |
na |
na |
na |
na |
| KERYX BIOPHARMACEUTICALS |
$12.66 |
64% |
483% |
$385 |
$51 |
$0 |
$334 |
$13.9 |
na |
na |
Jul-00 |
1.3 |
$10.00 |
$194 |
| METABASIS THERAPEUTICS |
$6.95 |
97% |
na |
$131 |
$57 |
$0 |
$74 |
$0.9 |
-$2 |
27.8 |
Jun-04 |
1.0 |
$7.00 |
$132 |
| NPS PHARMACEUTICALS |
$21.00 |
57% |
-16% |
$782 |
$266 |
$192 |
$708 |
$2.6 |
-$143 |
1.9 |
May-94 |
3.8 |
$5.50 |
$40 |
| SAVIENT PHARMACEUTICALS |
$2.48 |
37% |
-43% |
$149 |
$33 |
$11 |
$127 |
$0.3 |
na |
na |
Sep-83 |
0.2 |
$13.00 |
$68 |
| TERCICA |
$8.21 |
68% |
na |
$201 |
$74 |
$0 |
$127 |
$3.1 |
-$31 |
2.4 |
Mar-04 |
0.9 |
$9.00 |
$221 |
| VIVUS |
$3.64 |
49% |
-32% |
$141 |
$40 |
$0 |
$101 |
$0.9 |
-$44 |
0.9 |
Apr-94 |
0.5 |
$7.00 |
$164 |
| ZONAGEN |
$2.56 |
47% |
56% |
$13 |
$9 |
$0 |
$4 |
$1.1 |
-$3 |
2.7 |
Mar-93 |
0.5 |
$5.50 |
$19 |
| Metabolic Average |
|
60% |
49% |
$442 |
$99 |
|
$393 |
$3.6 |
-$59 |
5.1 |
|
1.1 |
|
|
| Metabolic Median |
|
57% |
-16% |
$149 |
$51 |
|
$127 |
$1.1 |
-$31 |
1.9 |
|
1.0 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/30/04 Close |
% of 52wk High |
% change from 6/27/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ALNYLAM PHARMACEUTICALS |
$7.56 |
80% |
na |
$146 |
$56 |
$2 |
$92 |
$1.5 |
-$56 |
1.0 |
May-04 |
1.3 |
$6.00 |
$116 |
| BARRIER THERAPEUTICS |
$14.01 |
89% |
na |
$305 |
$47 |
$0 |
$259 |
$6.3 |
-$44 |
1.1 |
Apr-04 |
0.9 |
$15.00 |
$327 |
| CRITICAL THERAPEUTICS |
$7.00 |
92% |
na |
$167 |
$62 |
$1 |
$107 |
$1.1 |
-$30 |
2.1 |
May-04 |
1.0 |
$7.00 |
$167 |
| EYETECH PHARMACEUTICALS |
$42.92 |
87% |
na |
$1,733 |
$270 |
$2 |
$1,464 |
$9.2 |
-$60 |
4.5 |
Jan-04 |
2.0 |
$21.00 |
$848 |
| MOMENTA PHARMACEUTICALS |
$8.85 |
93% |
na |
$217 |
$71 |
$0 |
$146 |
$4.1 |
-$10 |
6.8 |
Jun-04 |
1.4 |
$6.50 |
$160 |
| SANTARUS |
$14.75 |
93% |
na |
$432 |
$93 |
$1 |
$340 |
$4.9 |
-$41 |
2.3 |
Mar-04 |
1.6 |
$9.00 |
$263 |
| Other Average |
|
89% |
|
$500 |
$100 |
|
$401 |
$4.5 |
-$40 |
3.0 |
|
1.4 |
|
|
| Other Median |
|
92% |
|
$217 |
$62 |
|
$146 |
$4.1 |
-$41 |
2.1 |
|
1.3 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/30/04 Close |
% of 52wk High |
% change from 6/27/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| AMGEN |
$54.57 |
75% |
-16% |
$69,394 |
$5,003 |
$3,087 |
$67,478 |
$5.2 |
na |
na |
Jun-83 |
155.9 |
$0.35 |
$175 |
| BIOGEN IDEC |
$63.25 |
99% |
79% |
$21,490 |
$948 |
$861 |
$21,402 |
$5.7 |
-$165 |
5.8 |
Sep-91 |
25.3 |
$2.50 |
$131 |
| CHIRON CORP. |
$44.64 |
78% |
1% |
$8,435 |
$698 |
$1,088 |
$8,824 |
$1.7 |
na |
na |
Aug-83 |
14.9 |
$3.00 |
$98 |
| GENENTECH |
$56.20 |
82% |
53% |
$59,773 |
$1,815 |
$1,340 |
$59,298 |
$9.5 |
na |
na |
Oct-80 |
38.8 |
$1.45 |
$246 |
| GENZYME CORP. |
$47.33 |
81% |
10% |
$10,721 |
$1,004 |
$1,423 |
$11,141 |
$2.0 |
na |
na |
Jun-86 |
18.9 |
$2.50 |
$70 |
| GILEAD SCIENCES |
$67.00 |
95% |
19% |
$14,360 |
$1,036 |
$345 |
$13,669 |
$9.6 |
na |
na |
Jan-92 |
17.9 |
$3.75 |
$210 |
| Revenue-driven Average |
|
85% |
24% |
$30,695 |
$1,751 |
|
$30,302 |
$5.6 |
na |
na |
|
45.3 |
|
|
| Revenue-driven Median |
|
82% |
19% |
$14,360 |
$1,004 |
|
$13,669 |
$5.2 |
na |
na |
|
18.9 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/30/04 Close |
% of 52wk High |
% change from 6/27/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| DIVERSA CORP. |
$10.13 |
82% |
5% |
$438 |
$120 |
$20 |
$338 |
$0.9 |
-$41 |
2.9 |
Feb-00 |
0.4 |
$24.00 |
$840 |
| DYAX CORP. |
$11.75 |
75% |
194% |
$366 |
$436 |
$10 |
-$60 |
-$0.5 |
-$30 |
14.5 |
Aug-00 |
0.8 |
$15.00 |
$295 |
| ISIS PHARMACEUTICALS |
$5.74 |
58% |
6% |
$322 |
$189 |
$230 |
$363 |
$0.8 |
-$105 |
1.8 |
May-91 |
0.6 |
$10.00 |
$104 |
| LIGAND PHARMACEUTICALS ORPORATED |
$17.38 |
70% |
29% |
$1,280 |
$90 |
$174 |
$1,364 |
$3.0 |
-$52 |
1.7 |
Nov-92 |
2.1 |
$8.27 |
$131 |
| NEUROGEN CORP. |
$7.49 |
63% |
53% |
$256 |
$69 |
$14 |
$202 |
$1.3 |
-$28 |
2.4 |
Oct-89 |
1.2 |
$6.00 |
$35 |
| ONYX PHARMACEUTICALS |
$42.36 |
71% |
267% |
$1,468 |
$250 |
$0 |
$1,218 |
$76.1 |
-$33 |
7.6 |
May-96 |
3.5 |
$12.00 |
$105 |
| REGENERON PHARMACEUTICALS |
$10.53 |
47% |
-36% |
$586 |
$323 |
$200 |
$463 |
$7.2 |
na |
na |
Apr-91 |
0.5 |
$22.00 |
$330 |
| SENOMYX |
$6.25 |
81% |
na |
$154 |
$51 |
$0 |
$103 |
$1.4 |
-$20 |
2.6 |
Jun-04 |
1.0 |
$6.00 |
$148 |
| TULARIK |
$24.80 |
98% |
159% |
$1,670 |
$181 |
$26 |
$1,514 |
$3.7 |
-$95 |
1.9 |
Dec-99 |
1.8 |
$14.00 |
$636 |
| Screening Average |
|
72% |
85% |
$727 |
$190 |
|
$612 |
$10.4 |
-$51 |
4.4 |
|
1.3 |
|
|
| Screening Median |
|
73% |
53% |
$402 |
$150 |
|
$351 |
$1.4 |
-$33 |
2.4 |
|
1.0 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
6/30/04 Close |
% of 52wk High |
% change from 6/27/03 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/cash from IPO/share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| CARRINGTON LABORATORIES |
$4.45 |
69% |
68% |
$47 |
$3 |
$4 |
$49 |
$0.2 |
-$1 |
3.1 |
na |
na |
na |
na |
| CELLEGY PHARMACEUTICALS |
$3.90 |
56% |
-22% |
$78 |
$9 |
$0 |
$70 |
$3.5 |
-$12 |
0.7 |
Aug-95 |
0.6 |
$6.25 |
$24 |
| CURATIVE HEALTH SERVICES |
$8.66 |
46% |
-48% |
$112 |
$6 |
$0 |
$106 |
$0.3 |
na |
na |
Jun-91 |
1.2 |
$7.50 |
$74 |
| LIFECELL CORP. |
$11.23 |
98% |
114% |
$296 |
$19 |
$0 |
$277 |
$1.6 |
na |
na |
Feb-92 |
1.4 |
$7.75 |
$27 |
| LIFECORE BIOMEDICAL |
$6.14 |
74% |
8% |
$79 |
$8 |
$0 |
$71 |
$0.3 |
na |
na |
na |
na |
na |
na |
| Wound Average |
|
68% |
24% |
$122 |
$9 |
|
$114 |
$1.2 |
-$7 |
1.9 |
|
1.1 |
|
|
| Wound Median |
|
72% |
38% |
$79 |
$7 |
|
$70 |
$0.7 |
-$1 |
1.0 |
|
1.1 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Overall Average |
|
66% |
29% |
$1,286 |
$161 |
|
$1,211 |
$2.8 |
-$47 |
4.1 |
|
3.2 |
|
|
| Overall Median |
|
67% |
19% |
$247 |
$69 |
|
$192 |
$1.6 |
-$30 |
2.0 |
|
1.0 |
|
|
originally published 07/07/2004 |